,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okdd2AA'}, 'Id': 'a0POZ000009okdd2AA', 'Event_Date__c': '2018-08-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArV2QAK'}, 'change': None}]",Aug 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okde2AA'}, 'Id': 'a0POZ000009okde2AA', 'Event_Date__c': '2018-09-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArWAQA0'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended this with a medium priority, subject to criteria set out in the minutes.', 'fs': 'The Subcommittee recommended this with a medium priority, subject to criteria set out in the minutes.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2018-10.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2018-10.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2018', 'fs': 'Oct 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Wednesday 3 October 2018.', 'fs': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Wednesday 3 October 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okdf2AA'}, 'Id': 'a0POZ000009okdf2AA', 'Event_Date__c': '2018-10-03', 'Event_Description__c': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Wednesday 3 October 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2018-10.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a>', 'Outcome__c': 'Medium', 'Summary__c': 'The Subcommittee recommended this with a medium priority, subject to criteria set out in the minutes.', 'Formatted_Date__c': 'Oct 2018', 'Status_History__c': 'a132P000000ArY6QAK'}, 'change': None}, {'Summary': {'s': 'PTAC considered the advice of the Gastrointestinal Subcommittee, but instead recommended that a full paper be brought to PTAC for it to review.', 'fs': 'PTAC considered the advice of the Gastrointestinal Subcommittee, but instead recommended that a full paper be brought to PTAC for it to review.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okdg2AA'}, 'Id': 'a0POZ000009okdg2AA', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'PTAC considered the advice of the Gastrointestinal Subcommittee, but instead recommended that a full paper be brought to PTAC for it to review.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArbLQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that budesonide colonic release (CR) 9 mg for the treatment of mild to moderate ulcerative colitis be funded with a low priority, noting a small health benefit in patients who are unable to tolerate prednisone due to adverse effects, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt;"">Special Authority for Subsidy </b></p><p><b style=""font-size: 9pt;"">Initial application – (ulcerative colitis)</b><span style=""font-size: 9pt;""> from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has histologically confirmed left-sided or proctosigmoidal ulcerative colitis; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is aged 18 years or older; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Simple Clinical Colitis Activity Index (SCCAI) score of between 5 and 11; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has had an inadequate response following optimised therapy with 5-aminosalicylates; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Diabetes; or</span></p><p><span style=""font-size: 9pt;"">5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Cushingoid habitus; or</span></p><p><span style=""font-size: 9pt;"">5.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Osteoporosis where there is significant risk of fracture; or</span></p><p><span style=""font-size: 9pt;"">5.4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Severe acne following treatment with conventional corticosteroid therapy; or</span></p><p><span style=""font-size: 9pt;"">5.5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">History of severe psychiatric problems associated with corticosteroid treatment; or</span></p><p><span style=""font-size: 9pt;"">5.6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or</span></p><p><span style=""font-size: 9pt;"">5.7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Budesonide colonic release 9 mg tablets to be administered once daily for up to 8 weeks.</span></p><p><br></p><p><b style=""font-size: 9pt;"">Renewal </b><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment remains appropriate and the patient is benefiting from treatment; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Budesonide colonic release 9 mg tablets to be administered once daily for up to 8 weeks; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient can receive a maximum of two 8-week treatment cycles with budesonide colonic release 9 mg tablets within a 12-month period.</span></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that budesonide colonic release (CR) 9 mg for the treatment of mild to moderate ulcerative colitis be funded with a low priority, noting a small health benefit in patients who are unable to tolerate prednisone due to adverse effects, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt;"">Special Authority for Subsidy </b></p><p><b style=""font-size: 9pt;"">Initial application – (ulcerative colitis)</b><span style=""font-size: 9pt;""> from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has histologically confirmed left-sided or proctosigmoidal ulcerative colitis; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is aged 18 years or older; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Simple Clinical Colitis Activity Index (SCCAI) score of between 5 and 11; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has had an inadequate response following optimised therapy with 5-aminosalicylates; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Diabetes; or</span></p><p><span style=""font-size: 9pt;"">5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Cushingoid habitus; or</span></p><p><span style=""font-size: 9pt;"">5.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Osteoporosis where there is significant risk of fracture; or</span></p><p><span style=""font-size: 9pt;"">5.4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Severe acne following treatment with conventional corticosteroid therapy; or</span></p><p><span style=""font-size: 9pt;"">5.5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">History of severe psychiatric problems associated with corticosteroid treatment; or</span></p><p><span style=""font-size: 9pt;"">5.6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or</span></p><p><span style=""font-size: 9pt;"">5.7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Budesonide colonic release 9 mg tablets to be administered once daily for up to 8 weeks.</span></p><p><br></p><p><b style=""font-size: 9pt;"">Renewal </b><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment remains appropriate and the patient is benefiting from treatment; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Budesonide colonic release 9 mg tablets to be administered once daily for up to 8 weeks; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient can receive a maximum of two 8-week treatment cycles with budesonide colonic release 9 mg tablets within a 12-month period.</span></p>', 'change': None}, 'Published_Discussion': {'s': '<p><i style=""font-size: 11pt;"">Background</i></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2018-10.pdf"" target=""_blank"">October 2018</a> the Gastrointestinal Subcommittee reviewed the application for budesonide colonic release (CR) 9 mg and the Subcommittee recommended that budesonide CR 9 mg for the treatment of mild to moderate ulcerative colitis be funded with a medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a> PTAC reviewed the record from the October 2018 Gastrointestinal Subcommittee meeting, and PTAC did not accept the recommendations from the Subcommittee regarding budesonide CR 9 mg and requested that the Committee review a paper on budesonide CR 9 mg. The Committee noted that in February 2019 PTAC had concerns about what PTAC considered were the proposal’s modest reworking of the formulation, poor quality evidence, lack of clarity around an appropriate comparator for New Zealand, main benefit (likely to be avoidance of steroid side-effects) and likely high cost.</p><p><i style=""font-size: 11pt;"">Discussion</i></p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health need of patients with mild to moderate ulcerative colitis (UC) has been described in the previous Gastrointestinal Subcommittee and PTAC records. The Committee considered that UC is a long-term disease with a variable prognosis including relapses and remissions, and noted that UC reduces the quality of life of New Zealand patients with major impact in many areas (<a href=""https://issuu.com/crohnsandcolitisnz/docs/271017_master_formatted_bod_report_"" target=""_blank"">Crohn&#39;s Colitis New Zealand [CCNZ], 2017).</a></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that New Zealand patients with UC initially receive funded treatment with systemic or local 5-ASAs e.g. mesalazine, olsalazine or sulphasalazine; if these agents are insufficient, then oral steroids e.g. prednisone or hydrocortisone; are used, followed by immunosuppressants e.g. azathioprine or methotrexate, and then biologics for severe UC e.g. infliximab or adalimumab. The Committee noted that treatment with prednisone, even in other indications, is known to be associated with a predictable corticosteroid-related side effects in a proportion of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/20600032"" target=""_blank"">Manns et al. Gastroenterology. 2010:139;1198-206</a>).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients had better disease course long-term through actively managing disease flare ups. Members considered that while treatment of relapse is beneficial, most patients would require other treatments in time. The Committee considered that up to 25% of patients whose disease progresses require a colectomy within 10 years and 12-14% patients develop extra-intestinal disease. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide colonic release (CR) 9 mg is a specific formulation of budesonide, a second-generation glucocorticoid that is significantly more potent than prednisone, with a different mechanism of absorption as described in the Gastrointestinal Subcommittee record. The Committee considered that while budesonide CR 9 mg largely acts locally, it still has systemic effects.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide CR 9 mg is approved by Medsafe and internationally (and is funded in about half of countries where it is approved) for the induction of remission in adult patients with mild to moderate active UC where 5-ASA therapy has been not sufficient or not tolerated. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the current funding application specifically seeks funding of the CR formulation of budesonide and considered that the CR delivery was different but results in the same plasma concentration of budesonide and has a systemic effect. The Committee considered that the appropriate New Zealand comparator treatment for budesonide CR 9 mg would be prednisone, which is used as the standard of care treatment of mild to moderate UC that is not controlled by 5-ASA drugs.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide controlled ileal release (CIR) 3 mg (Entocort CIR) is currently funded, with use restricted to Crohn’s disease, microscopic colitis or gut Graft vs Host disease, and considered that budesonide CIR is used as a 9 mg dose with a similar treatment effect to prednisone 40 mg. Members noted that the Gastrointestinal Subcommittee had concerns about the side effect profile of prednisone, and considered that budesonide CIR is used for patients with Crohn’s disease especially in those unable to take or tolerate prednisone (~25% of patients with Crohn’s disease). Members considered that an alternative to prednisone for patients with UC may be useful.</p><p><i style=""font-size: 11pt;"">Evidence</i></p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the results of three randomised, double-blind, placebo-controlled clinical trials have been described in the Gastrointestinal Subcommittee record (CORE I, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/22892337"" target=""_blank"">Sandborn et al. Gastroenterology. 2012;143:1218-1226</a><u style=""color: blue;"">;</u> CORE II <a href=""https://www.ncbi.nlm.nih.gov/pubmed/23436336"" target=""_blank"">Travis et al. Gut. 2014;63:433-41</a><u style=""color: blue;"">;</u> and CONTRIBUTE <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28333362"" target=""_blank"">Rubin et al. J Crohns Colitis. 2017;11:785-791</a>). </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the CORE I trial (with mesalamine [5-ASA] comparator) and CORE II trial (with budesonide CIR [Entocort] 9 mg comparator) were similar studies, both having endoscopic and clinical remission endpoints. The Committee considered that these studies were not powered to assess clinical improvement, which the Gastrointestinal Subcommittee considered was the most important endpoint for patients with mild to moderate UC. The Committee noted that the CONTRIBUTE trial included clinical improvement as an exploratory endpoint, did not include any safety endpoints, and considered that the CONTRIBUTE trial criteria excluded patients less likely to respond to treatment.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the rate of combined clinical and endoscopic remission (CER) reported in CORE I was 17.9% with budesonide CR 9 mg compared to 7.4% with placebo, and the CER reported in CORE II was 17.4% with budesonide CR 9 mg compared to 4.5% with placebo. The Committee also noted that the rate of CER reported in CONTRIBUTE was 13% with budesonide CR 9 mg compared to 7.5% with placebo. The Committee noted clinical improvement (an important clinical endpoint) was not different between the budesonide 9 mg and placebo groups in the CORE I study, and clinical improvement was not different between budesonide and placebo in the CORE II study. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the CORE II results for combined clinical and endoscopic remission (CER) were similar between budesonide CR 9 mg (17.4%) and budesonide CIR (Entocort) 9 mg (12.6%) although the trial was not statistically powered for this comparison. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a pooled analysis of 5 clinical trials (including CORE I, CORE II, and others) and considered that the incidence of severe adverse events (AEs) and glucocorticoid AEs were similar across studies, and noted that glucocorticoid AEs occurred in less than 10% of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26094251"" target=""_blank"">Lichtenstein et al. J Crohns Colitis. 2015;9:738-746).</a> The Committee considered that the CORE I and CORE II trials were not designed to demonstrate a reduction in side effects.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a Cochrane systematic review of oral budesonide for induction of remission in UC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26497719"" target=""_blank"">Sherlock et al. Cochrane Database Syst Rev. 2015: Art. No. CD007698</a>), which reported that the evidence for clinical improvement and AEs was of low to moderate quality according to GRADE analysis. The Committee considered that the results suggest budesonide CR 9 mg is effective but offers no additional benefit than other standard of care treatments. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the clinical trials that provide the evidence for budesonide CR 9 mg did not include New Zealand participants. The Committee also noted that the clinical trials did not investigate or were not powered sufficiently to assess primary endpoints that are most clinically relevant in New Zealand (i.e. clinical improvement).</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are no clinical trials that directly compare the budesonide CR 9 mg formulation against prednisone, which would be the appropriate comparator for New Zealand and internationally. The Committee considered that the small clinical trial of budesonide 10 mg compared to prednisone 40 mg (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/8964395"" target=""_blank"">Löfberg et al. Gastroenterology. 1996:110;1713-8)</a> was not relevant due to use of a different budesonide formulation than this funding application’s. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the benefit of budesonide CR 9 mg compared to prednisone would be small, since prednisone already provides a health benefit over placebo. The Committee considered that further clinical trial data addressing this information gap was unlikely to be forthcoming. The Committee considered that the evidence does not suggest that there is a particular patient subgroup that would receive the most benefit from treatment with budesonide CR 9 mg. </p><p><i style=""font-size: 11pt;"">General</i></p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposed price of budesonide CR 9 mg was significantly higher than that of prednisone.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Gastrointestinal Subcommittee estimated that less than 3,000 patients each year may meet the Subcommittee’s proposed Special Authority criteria for treatment with budesonide CR 9 mg. </p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the Special Authority criteria proposed by the Gastrointestinal Subcommittee excludes patients for whom 5-ASA drugs are ineffective or not tolerated, but considered it appropriate that these patients access budesonide CR 9 mg. The Committee noted that the Simple Clinical Colitis Activity Index (SCCAI) scores require clinical assessment and considered that this introduced some subjectivity with inter-rater and test-retest variability in assessments, affecting validity. Members considered that the reason for a limited treatment duration of 16 weeks in the Special Authority (initial and renewal) was unclear.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that its view of the available evidence was less favourable than that of the Gastrointestinal Subcommittee and that budesonide CR 9 mg would provide only a small health benefit in patients who are unable to tolerate prednisone due to adverse effects; however, the Committee was supportive of funding budesonide CR 9 mg with a low priority.</p>', 'fs': '<p><i style=""font-size: 11pt;"">Background</i></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2018-10.pdf"" target=""_blank"">October 2018</a> the Gastrointestinal Subcommittee reviewed the application for budesonide colonic release (CR) 9 mg and the Subcommittee recommended that budesonide CR 9 mg for the treatment of mild to moderate ulcerative colitis be funded with a medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a> PTAC reviewed the record from the October 2018 Gastrointestinal Subcommittee meeting, and PTAC did not accept the recommendations from the Subcommittee regarding budesonide CR 9 mg and requested that the Committee review a paper on budesonide CR 9 mg. The Committee noted that in February 2019 PTAC had concerns about what PTAC considered were the proposal’s modest reworking of the formulation, poor quality evidence, lack of clarity around an appropriate comparator for New Zealand, main benefit (likely to be avoidance of steroid side-effects) and likely high cost.</p><p><i style=""font-size: 11pt;"">Discussion</i></p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health need of patients with mild to moderate ulcerative colitis (UC) has been described in the previous Gastrointestinal Subcommittee and PTAC records. The Committee considered that UC is a long-term disease with a variable prognosis including relapses and remissions, and noted that UC reduces the quality of life of New Zealand patients with major impact in many areas (<a href=""https://issuu.com/crohnsandcolitisnz/docs/271017_master_formatted_bod_report_"" target=""_blank"">Crohn&#39;s Colitis New Zealand [CCNZ], 2017).</a></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that New Zealand patients with UC initially receive funded treatment with systemic or local 5-ASAs e.g. mesalazine, olsalazine or sulphasalazine; if these agents are insufficient, then oral steroids e.g. prednisone or hydrocortisone; are used, followed by immunosuppressants e.g. azathioprine or methotrexate, and then biologics for severe UC e.g. infliximab or adalimumab. The Committee noted that treatment with prednisone, even in other indications, is known to be associated with a predictable corticosteroid-related side effects in a proportion of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/20600032"" target=""_blank"">Manns et al. Gastroenterology. 2010:139;1198-206</a>).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients had better disease course long-term through actively managing disease flare ups. Members considered that while treatment of relapse is beneficial, most patients would require other treatments in time. The Committee considered that up to 25% of patients whose disease progresses require a colectomy within 10 years and 12-14% patients develop extra-intestinal disease. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide colonic release (CR) 9 mg is a specific formulation of budesonide, a second-generation glucocorticoid that is significantly more potent than prednisone, with a different mechanism of absorption as described in the Gastrointestinal Subcommittee record. The Committee considered that while budesonide CR 9 mg largely acts locally, it still has systemic effects.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide CR 9 mg is approved by Medsafe and internationally (and is funded in about half of countries where it is approved) for the induction of remission in adult patients with mild to moderate active UC where 5-ASA therapy has been not sufficient or not tolerated. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the current funding application specifically seeks funding of the CR formulation of budesonide and considered that the CR delivery was different but results in the same plasma concentration of budesonide and has a systemic effect. The Committee considered that the appropriate New Zealand comparator treatment for budesonide CR 9 mg would be prednisone, which is used as the standard of care treatment of mild to moderate UC that is not controlled by 5-ASA drugs.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide controlled ileal release (CIR) 3 mg (Entocort CIR) is currently funded, with use restricted to Crohn’s disease, microscopic colitis or gut Graft vs Host disease, and considered that budesonide CIR is used as a 9 mg dose with a similar treatment effect to prednisone 40 mg. Members noted that the Gastrointestinal Subcommittee had concerns about the side effect profile of prednisone, and considered that budesonide CIR is used for patients with Crohn’s disease especially in those unable to take or tolerate prednisone (~25% of patients with Crohn’s disease). Members considered that an alternative to prednisone for patients with UC may be useful.</p><p><i style=""font-size: 11pt;"">Evidence</i></p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the results of three randomised, double-blind, placebo-controlled clinical trials have been described in the Gastrointestinal Subcommittee record (CORE I, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/22892337"" target=""_blank"">Sandborn et al. Gastroenterology. 2012;143:1218-1226</a><u style=""color: blue;"">;</u> CORE II <a href=""https://www.ncbi.nlm.nih.gov/pubmed/23436336"" target=""_blank"">Travis et al. Gut. 2014;63:433-41</a><u style=""color: blue;"">;</u> and CONTRIBUTE <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28333362"" target=""_blank"">Rubin et al. J Crohns Colitis. 2017;11:785-791</a>). </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the CORE I trial (with mesalamine [5-ASA] comparator) and CORE II trial (with budesonide CIR [Entocort] 9 mg comparator) were similar studies, both having endoscopic and clinical remission endpoints. The Committee considered that these studies were not powered to assess clinical improvement, which the Gastrointestinal Subcommittee considered was the most important endpoint for patients with mild to moderate UC. The Committee noted that the CONTRIBUTE trial included clinical improvement as an exploratory endpoint, did not include any safety endpoints, and considered that the CONTRIBUTE trial criteria excluded patients less likely to respond to treatment.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the rate of combined clinical and endoscopic remission (CER) reported in CORE I was 17.9% with budesonide CR 9 mg compared to 7.4% with placebo, and the CER reported in CORE II was 17.4% with budesonide CR 9 mg compared to 4.5% with placebo. The Committee also noted that the rate of CER reported in CONTRIBUTE was 13% with budesonide CR 9 mg compared to 7.5% with placebo. The Committee noted clinical improvement (an important clinical endpoint) was not different between the budesonide 9 mg and placebo groups in the CORE I study, and clinical improvement was not different between budesonide and placebo in the CORE II study. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the CORE II results for combined clinical and endoscopic remission (CER) were similar between budesonide CR 9 mg (17.4%) and budesonide CIR (Entocort) 9 mg (12.6%) although the trial was not statistically powered for this comparison. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a pooled analysis of 5 clinical trials (including CORE I, CORE II, and others) and considered that the incidence of severe adverse events (AEs) and glucocorticoid AEs were similar across studies, and noted that glucocorticoid AEs occurred in less than 10% of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26094251"" target=""_blank"">Lichtenstein et al. J Crohns Colitis. 2015;9:738-746).</a> The Committee considered that the CORE I and CORE II trials were not designed to demonstrate a reduction in side effects.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a Cochrane systematic review of oral budesonide for induction of remission in UC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26497719"" target=""_blank"">Sherlock et al. Cochrane Database Syst Rev. 2015: Art. No. CD007698</a>), which reported that the evidence for clinical improvement and AEs was of low to moderate quality according to GRADE analysis. The Committee considered that the results suggest budesonide CR 9 mg is effective but offers no additional benefit than other standard of care treatments. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the clinical trials that provide the evidence for budesonide CR 9 mg did not include New Zealand participants. The Committee also noted that the clinical trials did not investigate or were not powered sufficiently to assess primary endpoints that are most clinically relevant in New Zealand (i.e. clinical improvement).</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are no clinical trials that directly compare the budesonide CR 9 mg formulation against prednisone, which would be the appropriate comparator for New Zealand and internationally. The Committee considered that the small clinical trial of budesonide 10 mg compared to prednisone 40 mg (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/8964395"" target=""_blank"">Löfberg et al. Gastroenterology. 1996:110;1713-8)</a> was not relevant due to use of a different budesonide formulation than this funding application’s. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the benefit of budesonide CR 9 mg compared to prednisone would be small, since prednisone already provides a health benefit over placebo. The Committee considered that further clinical trial data addressing this information gap was unlikely to be forthcoming. The Committee considered that the evidence does not suggest that there is a particular patient subgroup that would receive the most benefit from treatment with budesonide CR 9 mg. </p><p><i style=""font-size: 11pt;"">General</i></p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposed price of budesonide CR 9 mg was significantly higher than that of prednisone.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Gastrointestinal Subcommittee estimated that less than 3,000 patients each year may meet the Subcommittee’s proposed Special Authority criteria for treatment with budesonide CR 9 mg. </p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the Special Authority criteria proposed by the Gastrointestinal Subcommittee excludes patients for whom 5-ASA drugs are ineffective or not tolerated, but considered it appropriate that these patients access budesonide CR 9 mg. The Committee noted that the Simple Clinical Colitis Activity Index (SCCAI) scores require clinical assessment and considered that this introduced some subjectivity with inter-rater and test-retest variability in assessments, affecting validity. Members considered that the reason for a limited treatment duration of 16 weeks in the Special Authority (initial and renewal) was unclear.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that its view of the available evidence was less favourable than that of the Gastrointestinal Subcommittee and that budesonide CR 9 mg would provide only a small health benefit in patients who are unable to tolerate prednisone due to adverse effects; however, the Committee was supportive of funding budesonide CR 9 mg with a low priority.</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for budesonide colonic release (CR) 9 mg for the treatment of mild to moderate ulcerative colitis from Pharmaco (NZ) Ltd. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for budesonide colonic release (CR) 9 mg for the treatment of mild to moderate ulcerative colitis from Pharmaco (NZ) Ltd. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okdh2AA'}, 'Id': 'a0POZ000009okdh2AA', 'Event_Date__c': '2019-11-22', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Nov 2019', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that budesonide colonic release (CR) 9 mg for the treatment of mild to moderate ulcerative colitis be funded with a low priority, noting a small health benefit in patients who are unable to tolerate prednisone due to adverse effects, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt;"">Special Authority for Subsidy </b></p><p><b style=""font-size: 9pt;"">Initial application – (ulcerative colitis)</b><span style=""font-size: 9pt;""> from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has histologically confirmed left-sided or proctosigmoidal ulcerative colitis; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is aged 18 years or older; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Simple Clinical Colitis Activity Index (SCCAI) score of between 5 and 11; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has had an inadequate response following optimised therapy with 5-aminosalicylates; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Diabetes; or</span></p><p><span style=""font-size: 9pt;"">5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Cushingoid habitus; or</span></p><p><span style=""font-size: 9pt;"">5.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Osteoporosis where there is significant risk of fracture; or</span></p><p><span style=""font-size: 9pt;"">5.4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Severe acne following treatment with conventional corticosteroid therapy; or</span></p><p><span style=""font-size: 9pt;"">5.5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">History of severe psychiatric problems associated with corticosteroid treatment; or</span></p><p><span style=""font-size: 9pt;"">5.6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or</span></p><p><span style=""font-size: 9pt;"">5.7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated)</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Budesonide colonic release 9 mg tablets to be administered once daily for up to 8 weeks.</span></p><p><br></p><p><b style=""font-size: 9pt;"">Renewal </b><span style=""font-size: 9pt;"">from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment remains appropriate and the patient is benefiting from treatment; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Budesonide colonic release 9 mg tablets to be administered once daily for up to 8 weeks; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient can receive a maximum of two 8-week treatment cycles with budesonide colonic release 9 mg tablets within a 12-month period.</span></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for budesonide colonic release (CR) 9 mg for the treatment of mild to moderate ulcerative colitis from Pharmaco (NZ) Ltd. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><i style=""font-size: 11pt;"">Background</i></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2018-10.pdf"" target=""_blank"">October 2018</a> the Gastrointestinal Subcommittee reviewed the application for budesonide colonic release (CR) 9 mg and the Subcommittee recommended that budesonide CR 9 mg for the treatment of mild to moderate ulcerative colitis be funded with a medium priority, subject to Special Authority criteria.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a> PTAC reviewed the record from the October 2018 Gastrointestinal Subcommittee meeting, and PTAC did not accept the recommendations from the Subcommittee regarding budesonide CR 9 mg and requested that the Committee review a paper on budesonide CR 9 mg. The Committee noted that in February 2019 PTAC had concerns about what PTAC considered were the proposal’s modest reworking of the formulation, poor quality evidence, lack of clarity around an appropriate comparator for New Zealand, main benefit (likely to be avoidance of steroid side-effects) and likely high cost.</p><p><i style=""font-size: 11pt;"">Discussion</i></p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the health need of patients with mild to moderate ulcerative colitis (UC) has been described in the previous Gastrointestinal Subcommittee and PTAC records. The Committee considered that UC is a long-term disease with a variable prognosis including relapses and remissions, and noted that UC reduces the quality of life of New Zealand patients with major impact in many areas (<a href=""https://issuu.com/crohnsandcolitisnz/docs/271017_master_formatted_bod_report_"" target=""_blank"">Crohn&#39;s Colitis New Zealand [CCNZ], 2017).</a></p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that New Zealand patients with UC initially receive funded treatment with systemic or local 5-ASAs e.g. mesalazine, olsalazine or sulphasalazine; if these agents are insufficient, then oral steroids e.g. prednisone or hydrocortisone; are used, followed by immunosuppressants e.g. azathioprine or methotrexate, and then biologics for severe UC e.g. infliximab or adalimumab. The Committee noted that treatment with prednisone, even in other indications, is known to be associated with a predictable corticosteroid-related side effects in a proportion of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/20600032"" target=""_blank"">Manns et al. Gastroenterology. 2010:139;1198-206</a>).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients had better disease course long-term through actively managing disease flare ups. Members considered that while treatment of relapse is beneficial, most patients would require other treatments in time. The Committee considered that up to 25% of patients whose disease progresses require a colectomy within 10 years and 12-14% patients develop extra-intestinal disease. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide colonic release (CR) 9 mg is a specific formulation of budesonide, a second-generation glucocorticoid that is significantly more potent than prednisone, with a different mechanism of absorption as described in the Gastrointestinal Subcommittee record. The Committee considered that while budesonide CR 9 mg largely acts locally, it still has systemic effects.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide CR 9 mg is approved by Medsafe and internationally (and is funded in about half of countries where it is approved) for the induction of remission in adult patients with mild to moderate active UC where 5-ASA therapy has been not sufficient or not tolerated. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the current funding application specifically seeks funding of the CR formulation of budesonide and considered that the CR delivery was different but results in the same plasma concentration of budesonide and has a systemic effect. The Committee considered that the appropriate New Zealand comparator treatment for budesonide CR 9 mg would be prednisone, which is used as the standard of care treatment of mild to moderate UC that is not controlled by 5-ASA drugs.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that budesonide controlled ileal release (CIR) 3 mg (Entocort CIR) is currently funded, with use restricted to Crohn’s disease, microscopic colitis or gut Graft vs Host disease, and considered that budesonide CIR is used as a 9 mg dose with a similar treatment effect to prednisone 40 mg. Members noted that the Gastrointestinal Subcommittee had concerns about the side effect profile of prednisone, and considered that budesonide CIR is used for patients with Crohn’s disease especially in those unable to take or tolerate prednisone (~25% of patients with Crohn’s disease). Members considered that an alternative to prednisone for patients with UC may be useful.</p><p><i style=""font-size: 11pt;"">Evidence</i></p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the results of three randomised, double-blind, placebo-controlled clinical trials have been described in the Gastrointestinal Subcommittee record (CORE I, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/22892337"" target=""_blank"">Sandborn et al. Gastroenterology. 2012;143:1218-1226</a><u style=""color: blue;"">;</u> CORE II <a href=""https://www.ncbi.nlm.nih.gov/pubmed/23436336"" target=""_blank"">Travis et al. Gut. 2014;63:433-41</a><u style=""color: blue;"">;</u> and CONTRIBUTE <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28333362"" target=""_blank"">Rubin et al. J Crohns Colitis. 2017;11:785-791</a>). </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the CORE I trial (with mesalamine [5-ASA] comparator) and CORE II trial (with budesonide CIR [Entocort] 9 mg comparator) were similar studies, both having endoscopic and clinical remission endpoints. The Committee considered that these studies were not powered to assess clinical improvement, which the Gastrointestinal Subcommittee considered was the most important endpoint for patients with mild to moderate UC. The Committee noted that the CONTRIBUTE trial included clinical improvement as an exploratory endpoint, did not include any safety endpoints, and considered that the CONTRIBUTE trial criteria excluded patients less likely to respond to treatment.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the rate of combined clinical and endoscopic remission (CER) reported in CORE I was 17.9% with budesonide CR 9 mg compared to 7.4% with placebo, and the CER reported in CORE II was 17.4% with budesonide CR 9 mg compared to 4.5% with placebo. The Committee also noted that the rate of CER reported in CONTRIBUTE was 13% with budesonide CR 9 mg compared to 7.5% with placebo. The Committee noted clinical improvement (an important clinical endpoint) was not different between the budesonide 9 mg and placebo groups in the CORE I study, and clinical improvement was not different between budesonide and placebo in the CORE II study. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the CORE II results for combined clinical and endoscopic remission (CER) were similar between budesonide CR 9 mg (17.4%) and budesonide CIR (Entocort) 9 mg (12.6%) although the trial was not statistically powered for this comparison. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a pooled analysis of 5 clinical trials (including CORE I, CORE II, and others) and considered that the incidence of severe adverse events (AEs) and glucocorticoid AEs were similar across studies, and noted that glucocorticoid AEs occurred in less than 10% of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26094251"" target=""_blank"">Lichtenstein et al. J Crohns Colitis. 2015;9:738-746).</a> The Committee considered that the CORE I and CORE II trials were not designed to demonstrate a reduction in side effects.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a Cochrane systematic review of oral budesonide for induction of remission in UC (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26497719"" target=""_blank"">Sherlock et al. Cochrane Database Syst Rev. 2015: Art. No. CD007698</a>), which reported that the evidence for clinical improvement and AEs was of low to moderate quality according to GRADE analysis. The Committee considered that the results suggest budesonide CR 9 mg is effective but offers no additional benefit than other standard of care treatments. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the clinical trials that provide the evidence for budesonide CR 9 mg did not include New Zealand participants. The Committee also noted that the clinical trials did not investigate or were not powered sufficiently to assess primary endpoints that are most clinically relevant in New Zealand (i.e. clinical improvement).</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are no clinical trials that directly compare the budesonide CR 9 mg formulation against prednisone, which would be the appropriate comparator for New Zealand and internationally. The Committee considered that the small clinical trial of budesonide 10 mg compared to prednisone 40 mg (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/8964395"" target=""_blank"">Löfberg et al. Gastroenterology. 1996:110;1713-8)</a> was not relevant due to use of a different budesonide formulation than this funding application’s. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the benefit of budesonide CR 9 mg compared to prednisone would be small, since prednisone already provides a health benefit over placebo. The Committee considered that further clinical trial data addressing this information gap was unlikely to be forthcoming. The Committee considered that the evidence does not suggest that there is a particular patient subgroup that would receive the most benefit from treatment with budesonide CR 9 mg. </p><p><i style=""font-size: 11pt;"">General</i></p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposed price of budesonide CR 9 mg was significantly higher than that of prednisone.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Gastrointestinal Subcommittee estimated that less than 3,000 patients each year may meet the Subcommittee’s proposed Special Authority criteria for treatment with budesonide CR 9 mg. </p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the Special Authority criteria proposed by the Gastrointestinal Subcommittee excludes patients for whom 5-ASA drugs are ineffective or not tolerated, but considered it appropriate that these patients access budesonide CR 9 mg. The Committee noted that the Simple Clinical Colitis Activity Index (SCCAI) scores require clinical assessment and considered that this introduced some subjectivity with inter-rater and test-retest variability in assessments, affecting validity. Members considered that the reason for a limited treatment duration of 16 weeks in the Special Authority (initial and renewal) was unclear.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that its view of the available evidence was less favourable than that of the Gastrointestinal Subcommittee and that budesonide CR 9 mg would provide only a small health benefit in patients who are unable to tolerate prednisone due to adverse effects; however, the Committee was supportive of funding budesonide CR 9 mg with a low priority.</p>', 'Status_History__c': 'a132P000000BAYhQAO'}, 'change': None}]",Sep 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okdi2AA'}, 'Id': 'a0POZ000009okdi2AA', 'Event_Date__c': '2020-01-13', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BNcOQAW'}, 'change': None}]",Jan 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2020', 'fs': 'Nov 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okdj2AA'}, 'Id': 'a0POZ000009okdj2AA', 'Event_Date__c': '2020-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2020', 'Status_History__c': 'a132P000000CKAjQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009okdk2AA'}, 'Id': 'a0POZ000009okdk2AA', 'Event_Date__c': '2021-03-11', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CfrQQAS'}, 'change': None}]",Nov 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
